-
EP4201404
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4201404
| EP4201404 - ANTIVIRAL COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 29.12.2023 Database last updated on 02.11.2024 | |
| Former | The application has been published Status updated on 26.05.2023 | Most recent event Tooltip | 23.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Erasmus University Rotterdam Medical Center Dr. Molewaterplein 50 3015 GE Rotterdam / NL | For all designated states Purdue Research Foundation 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 / US | [2023/26] | Inventor(s) | 01 /
DYKHUIZEN, Emily Carla West Lafayette, 47906 / US | 02 /
LAMERS, Mart Matthias 3015 GE Rotterdam / NL | 03 /
HAAGMANS, Bartholomeus Leonardus 3015 GE Rotterdam / NL | 04 /
MAHMOUDI, Tokameh 3015 GE Rotterdam / NL | [2023/26] | Representative(s) | V.O. P.O. Box 87930 2508 DH Den Haag / NL | [2023/26] | Application number, filing date | 22153463.9 | 26.01.2022 | [2023/26] | Priority number, date | US202163292032P | 21.12.2021 Original published format: US 202163292032 P | [2023/26] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4201404 | Date: | 28.06.2023 | Language: | EN | [2023/26] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 19.07.2022 | Classification | IPC: | A61K31/395, A61P31/12, A61K9/00 | [2023/26] | CPC: |
A61K31/395 (EP);
C07D273/08 (US);
A61K9/0019 (US);
A61K9/0043 (US);
A61P31/12 (EP);
C07D413/10 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/05] |
| Former [2023/26] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | ANTIVIRALE VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG VON CORONAVIRUS-INFEKTIONEN | [2023/26] | English: | ANTIVIRAL COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | [2023/26] | French: | COMPOSÉS ANTIVIRAUX À UTILISER DANS LE TRAITEMENT D'UNE INFECTION À CORONAVIRUS | [2023/26] | Examination procedure | 22.12.2023 | Amendment by applicant (claims and/or description) | 22.12.2023 | Examination requested [2024/05] | 22.12.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 23.01.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2009026527 (NOVOBIOTIC PHARMACEUTICALS LLC [US], et al) [A] 1-15 * page 34, line 20 - line 21 *; | [X]WO2020014524 (UNIV LELAND STANFORD JUNIOR [US], et al) [X] 1-8,13-15 * claims 1-26 * * page 60, line 13 - line 17 *; | [I]WO2021191312 (BAUSCH HEALTH IRELAND LTD [IE]) [I] 1-15 * claims *; | [X] - MARIAN CHRISTINE A ET AL, "Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal", CELL CHEMICAL BIOLOGY , ELSEVIER, AMSTERDAM, NL, (20180906), vol. 25, no. 12, doi:10.1016/J.CHEMBIOL.2018.08.004, ISSN 2451-9456, page 1443, XP085563561 [X] 1-8,13-15 * abstract * DOI: http://dx.doi.org/10.1016/j.chembiol.2018.08.004 | [A] - SHIRVALILOO MILAD, "Epigenomics in COVID-19; the link between DNA methylation, histone modifications and SARS-CoV-2 infection", EPIGENOMICS, United Kingdom, (20210501), vol. 13, no. 10, doi:10.2217/epi-2021-0057, ISSN 1750-1911, pages 745 - 750, XP055937965 [A] 1-15 * first paragraph; page 748 * DOI: http://dx.doi.org/10.2217/epi-2021-0057 | by applicant | WO2020014524 | US2020255416 | - WEI et al., Cell, (20210000), vol. 184, pages 76 - 91 | - MARIAN et al., Cell Chemical Biology, (20180000), vol. 25, pages 1443 - 1455 | - LAMERS et al., EMBO J., (20200000), vol. 40, no. 5, page el059l2 | - LAMERS et al., Elife, (20210000), vol. 10, page e66815 | - CAS, no. 1357647-78-9 | - LAMERS et al., EMBO Journal, (20210000), vol. 40, page e1059l2 | - LAMERS et al., Science, (20200000), vol. 369, no. 6499, pages 50 - 54 |